The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Superiority of durvalumab versus atezolizumab in extensive-stage SCLC
Apar Ganti, MD, University of Nebraska Medical Center, Omaha, NE, shares insights into the comparison of atezolizumab and durvalumab for extensive-stage small cell lung cancer (SCLC). Prof. Ganti highlights the similar median overall survival for both agents from real-world data, noting also that data to be presented may show a superiority in overall survival for durvalumab. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
